TiO2-Nanowired Delivery of DL-3-n-butylphthalide (DL-NBP) Attenuates Blood-Brain Barrier Disruption, Brain Edema Formation, and Neuronal Damages Following Concussive Head Injury
- PMID: 28856586
- DOI: 10.1007/s12035-017-0746-5
TiO2-Nanowired Delivery of DL-3-n-butylphthalide (DL-NBP) Attenuates Blood-Brain Barrier Disruption, Brain Edema Formation, and Neuronal Damages Following Concussive Head Injury
Abstract
DL-3-n-butylphthalide (DL-NBP) is one of the constituents of Chinese celery extract that is used to treat stroke, dementia, and ischemic diseases. However, its role in traumatic brain injury is less well known. In this investigation, neuroprotective effects of DL-NBP in concussive head injury (CHI) on brain pathology were explored in a rat model. CHI was inflicted in anesthetized rats by dropping a weight of 114.6 g from a height of 20 cm through a guide tube on the exposed right parietal bone inducing an impact of 0.224 N and allowed them to survive 4 to 24 h after the primary insult. DL-NBP was administered (40 or 60 mg/kg, i.p.) 2 and 4 h after injury in 8-h survival group and 8 and 12 h after trauma in 24-h survival group. In addition, TiO2-nanowired delivery of DL-NBP (20 or 40 mg/kg, i.p.) in 8 and 24 h CHI rats was also examined. Untreated CHI showed a progressive increase in blood-brain barrier (BBB) breakdown to Evans blue albumin (EBA) and radioiodine ([131]-I), edema formation, and neuronal injuries. The magnitude and intensity of these pathological changes were most marked in the left hemisphere. Treatment with DL-NBP significantly reduced brain pathology in CHI following 8 to 12 h at 40-mg dose. However, 60-mg dose is needed to thwart brain pathology at 24 h following CHI. On the other hand, TiO2-DL-NBP was effective in reducing brain damage up to 8 or 12 h using a 20-mg dose and only 40-mg dose was needed for neuroprotection in CHI at 24 h. These observations are the first to suggest that (i) DL-NBP is quite effective in reducing brain pathology and (ii) nanodelivery of DL-NBP has far more superior effects in CHI, not reported earlier.
Keywords: Blood-brain barrier; Brain edema; Concussive head injury (CHI); DL-3-n-butylphthalide (DL-NBP); Neuronal injury; Neuroprotection; TiO2 nanodelivery.
Similar articles
-
Nanowired delivery of DL-3-n-butylphthalide induces superior neuroprotection in concussive head injury.Prog Brain Res. 2019;245:89-118. doi: 10.1016/bs.pbr.2019.03.008. Epub 2019 Apr 2. Prog Brain Res. 2019. PMID: 30961873 Review.
-
Potentiation of spinal cord conduction and neuroprotection following nanodelivery of DL-3-n-butylphthalide in titanium implanted nanomaterial in a focal spinal cord injury induced functional outcome, blood-spinal cord barrier breakdown and edema formation.Int Rev Neurobiol. 2019;146:153-188. doi: 10.1016/bs.irn.2019.06.009. Epub 2019 Jul 8. Int Rev Neurobiol. 2019. PMID: 31349926
-
Repeated Forced Swim Exacerbates Methamphetamine-Induced Neurotoxicity: Neuroprotective Effects of Nanowired Delivery of 5-HT3-Receptor Antagonist Ondansetron.Mol Neurobiol. 2018 Jan;55(1):322-334. doi: 10.1007/s12035-017-0744-7. Mol Neurobiol. 2018. PMID: 28861718
-
Co-administration of dl-3-n-butylphthalide and neprilysin is neuroprotective in Alzheimer disease associated with mild traumatic brain injury.Int Rev Neurobiol. 2023;172:145-185. doi: 10.1016/bs.irn.2023.06.006. Epub 2023 Sep 26. Int Rev Neurobiol. 2023. PMID: 37833011
-
Co-administration of Nanowired DL-3-n-Butylphthalide (DL-NBP) Together with Mesenchymal Stem Cells, Monoclonal Antibodies to Alpha Synuclein and TDP-43 (TAR DNA-Binding Protein 43) Enhance Superior Neuroprotection in Parkinson's Disease Following Concussive Head Injury.Adv Neurobiol. 2023;32:97-138. doi: 10.1007/978-3-031-32997-5_3. Adv Neurobiol. 2023. PMID: 37480460 Review.
Cited by
-
Co-administration of Nanowired Oxiracetam and Neprilysin with Monoclonal Antibodies to Amyloid Beta Peptide and p-Tau Thwarted Exacerbation of Brain Pathology in Concussive Head Injury at Hot Environment.Adv Neurobiol. 2023;32:271-313. doi: 10.1007/978-3-031-32997-5_7. Adv Neurobiol. 2023. PMID: 37480464 Review.
-
DL-3-n-butylphthalide for acute ischemic stroke: An updated systematic review and meta-analysis of randomized controlled trials.Front Pharmacol. 2022 Sep 2;13:963118. doi: 10.3389/fphar.2022.963118. eCollection 2022. Front Pharmacol. 2022. PMID: 36120291 Free PMC article.
-
Protective multi‑target effects of DL‑3‑n‑butylphthalide combined with 3‑methyl‑1‑phenyl‑2‑pyrazolin‑5‑one in mice with ischemic stroke.Mol Med Rep. 2021 Dec;24(6):850. doi: 10.3892/mmr.2021.12490. Epub 2021 Oct 13. Mol Med Rep. 2021. PMID: 34643246 Free PMC article.
-
Nanowired Delivery of Cerebrolysin Together with Antibodies to Amyloid Beta Peptide, Phosphorylated Tau, and Tumor Necrosis Factor Alpha Induces Superior Neuroprotection in Alzheimer's Disease Brain Pathology Exacerbated by Sleep Deprivation.Adv Neurobiol. 2023;32:3-53. doi: 10.1007/978-3-031-32997-5_1. Adv Neurobiol. 2023. PMID: 37480458 Review.
-
DL-3-n-butylphthalide protects the blood-brain barrier against ischemia/hypoxia injury via upregulation of tight junction proteins.Chin Med J (Engl). 2019 Jun 5;132(11):1344-1353. doi: 10.1097/CM9.0000000000000232. Chin Med J (Engl). 2019. PMID: 30939485 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical